News

The company has filed the marketing applications on the basis of the results from two 26-week Phase 2 studies evaluating Soliris as a treatment for adult and adolescent

As per the agreement, KellBenx is expected to get worldwide rights for the commercialization of the antibodies which allow the extraction of clinically relevant information from maternal blood

Following the merger, the combined entity will be known as Astex Pharmaceuticals and will focus on oncology drug discovery, development and commercialization. Pursuant to the terms of the

Funding is in the form of one SBIR Phase 1 award titled ‘effects of P-188 on respiratory function and diaphragm degeneration in the mdx mouse’ and STTR phase

Rivaroxaban is a novel oral anticoagulant being evaluated for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role. Rivaroxaban

The experts at the Adaptive Clinical Trials Innovation Center work with clients to assist with the trial design, simulation and execution, develop adaptive trials software tools, and work

Under the agreement, OBT will use Potelligent Technology for the manufacturing, development and commercializing chosen ADCC programs from its pipeline of preclinical antibodies for oncology, which it has

The two programs were part of Sunesis multi-kinase inhibitor collaboration with Biogen Idec, which was signed in 2004. Further in 2010, Biogen Idec has out licensed all its

GliaMed will be eligible to receive up to 8,205 shares of newly designated Series E Preferred Stock, which would be convertible into approximately 20% of the company’s fully